Can you take Allogeneic regulatory T cell immunotherapy with HSPC and T cells with Beclomethasone?
1 drug interaction and 8 additional warnings found for the following 2 drugs:
- allogeneic regulatory T cell immunotherapy with HSPC and T cells
- beclomethasone
Drug interactions
Major drug interactions
Major:
beclomethasone allogeneic regulatory T cell immunotherapy with HSPC and T cells
Applies to: beclomethasone and allogeneic regulatory T cell immunotherapy with HSPC and T cells
Beclomethasone may reduce the effectiveness of allogeneic regulatory T cell immunotherapy with HSPC and T cells. Speak with your healthcare provider before using allogeneic regulatory T cell immunotherapy with HSPC and T cells together with beclomethasone, especially if being used immediately prior to your treatment with allogeneic regulatory T cell immunotherapy with HSPC and T cells. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
8 potential interactions Applies to: 8 conditions, including Osteoporosis, Cataract, Liver Disease, Infection, and Tuberculosis, Latent.
Cataract
Moderate:
beclomethasone
Beclomethasone has a moderate potential interaction with Cataract.
Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves. Therapy with corticosteroids should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure. Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished. Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used. It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.
Glaucoma/Intraocular Hypertension
Moderate:
beclomethasone
Beclomethasone has a moderate potential interaction with Glaucoma/Intraocular Hypertension.
Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves. Therapy with corticosteroids should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure. Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished. Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used. It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.
Herpetic Keratitis
Moderate:
beclomethasone
Beclomethasone has a moderate potential interaction with Herpetic Keratitis.
Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex. Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.
Hyperadrenocorticism
Moderate:
beclomethasone
Beclomethasone has a moderate potential interaction with Hyperadrenocorticism.
The use of corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism. Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished. Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used. It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used. The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.
Infection
Moderate:
beclomethasone
Beclomethasone has a moderate potential interaction with Infection.
The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection. Secondary infections may be more likely to develop. Therapy with corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis or in hepatitis B carriers. Monitor patients for any new or worsening infection and use with caution in these patients. A serious or even fatal course of chickenpox and measles can occur in susceptible patients. It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.
Liver Disease
Moderate:
beclomethasone
Beclomethasone has a moderate potential interaction with Liver Disease.
Corticosteroids are predominantly cleared by hepatic metabolism and impairment of the liver function may lead to their accumulation. Patients with hepatic disease should be closely monitored.
Osteoporosis
Moderate:
beclomethasone
Beclomethasone has a moderate potential interaction with Osteoporosis.
Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density. This effect appears to be dose-related and has been reported primarily with high dosages (800 mcg/day or more of beclomethasone or equivalent for 1 year or greater). Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages. Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis. It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.
Tuberculosis, Latent
Moderate:
beclomethasone
Beclomethasone has a moderate potential interaction with Tuberculosis, Latent.
The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection. Secondary infections may be more likely to develop. Therapy with corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis or in hepatitis B carriers. Monitor patients for any new or worsening infection and use with caution in these patients. A serious or even fatal course of chickenpox and measles can occur in susceptible patients. It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.
More resources
allogeneic regulatory T cell immunotherapy with HSPC and T cells
A total of 14 drugs are known to interact with allogeneic regulatory T cell immunotherapy with HSPC and T cells.
- Allogeneic regulatory t cell immunotherapy with hspc and t cells is in the drug class miscellaneous uncategorized agents.
- Allogeneic regulatory t cell immunotherapy with hspc and t cells is used to treat the following conditions:
beclomethasone
A total of 85 drugs are known to interact with beclomethasone.
- Beclomethasone is in the drug class inhaled corticosteroids.
- Beclomethasone is used to treat the following conditions:
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.